Novel benzodiazepines in illicit drug use: sentinel emergency department data do not indicate disproportionate clinical harm.

BACKGROUND

Novel or unregulated benzodiazepines are increasingly detected in illicit drug markets and may be perceived to pose greater clinical risk than regulated pharmaceutical benzodiazepines. However, much of the evidence underpinning these concerns derives from case reports, surveillance data, and settings characterised by extensive polysubstance exposure. We examined whether detection of novel/unregulated benzodiazepines is associated with greater acute clinical severity than pharmaceutical benzodiazepines in emergency department cases.

METHODS

We conducted a retrospective analysis of the Emerging Drugs Network of Australia- Victoria (EDNAV) clinical registry, including analytically confirmed benzodiazepine-positive cases between 1 September 2020 and 30 November 2025. Cases were classified as involving novel/unregulated benzodiazepines (with or without pharmaceutical benzodiazepines) or pharmaceutical benzodiazepines only. Primary outcomes included severe toxicity (any of - intensive care unit admission, intubation, vasopressor use), respiratory depression, Poisoning Severity Score (PSS ≥3), and in-hospital mortality. Multivariable logistic regression was used to estimate adjusted odds ratios (aORs), accounting for age, sex, and co-detection of opioids, stimulants, and gamma-hydroxybutyrate (GHB).

RESULTS

Among 2,638 benzodiazepine-positive cases, 772 cases involved detection of at least one novel/unregulated benzodiazepine (with or without concurrent pharmaceutical benzodiazepines) and 1,866 involved pharmaceutical benzodiazepines without any novel/unregulated benzodiazepines detected. Unadjusted analyses showed lower rates of several severe outcomes in the novel/unregulated group. After adjustment, detection of novel/unregulated benzodiazepines was not associated with increased odds of severe toxicity (aOR 0.84, 95% CI 0.67-1.06) or PSS ≥3 (aOR 1.00, 95% CI 0.83-1.21). Opioid and GHB co-detection were the strongest predictors of severe outcomes.

CONCLUSIONS

In this analytically confirmed cohort, novel/unregulated benzodiazepines were not associated with greater acute clinical severity than pharmaceutical benzodiazepines once polysubstance exposure was accounted for. These findings suggest that observed acute benzodiazepine-related harms are driven primarily by patterns of co-use, particularly opioid co-exposure, rather than regulatory status of benzodiazepine compounds.